Literature DB >> 31862759

16. Diabetes Advocacy: Standards of Medical Care in Diabetes-2019.

.   

Abstract

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
© 2019 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2020        PMID: 31862759     DOI: 10.2337/dc20-S016

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  17 in total

1.  Community-Based Participatory Research Interventions to Improve Diabetes Outcomes: A Systematic Review.

Authors:  Jennifer A Campbell; Alice Yan; Leonard E Egede
Journal:  Diabetes Educ       Date:  2020-10-14       Impact factor: 2.140

2.  Battlefield Endocrinology.

Authors:  Archana R Sadhu
Journal:  J Diabetes Sci Technol       Date:  2020-06-02

3.  Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.

Authors:  Julio A Lamprea-Montealegre; Erin Madden; Sri Lekha Tummalapalli; Carmen Peralta; Torsten B Neilands; Paola K Garcia; Anthony Muiru; Leah Karliner; Michael G Shlipak; Michelle M Estrella
Journal:  JAMA       Date:  2022-09-06       Impact factor: 157.335

4.  Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.

Authors:  Angela H E M Maas; Giuseppe Rosano; Renata Cifkova; Alaide Chieffo; Dorenda van Dijken; Haitham Hamoda; Vijay Kunadian; Ellen Laan; Irene Lambrinoudaki; Kate Maclaran; Nick Panay; John C Stevenson; Mick van Trotsenburg; Peter Collins
Journal:  Eur Heart J       Date:  2021-03-07       Impact factor: 29.983

5.  A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.

Authors:  Mike Baxter; Yukiko Morimoto; Masami Tamiwa; Masakatsu Hattori; Xuejun Victor Peng; Robert Lubwama; Hiroshi Maegawa
Journal:  Diabetes Ther       Date:  2020-05-22       Impact factor: 2.945

6.  What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient.

Authors:  W David Strain; Carmen Tsang; Michael Hurst; Phil McEwan; Minesh Unadkat; Simon Meadowcroft; Richard Shardlow; Marc Evans
Journal:  Diabetes Ther       Date:  2020-05-18       Impact factor: 2.945

Review 7.  Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies.

Authors:  Gratiela Gradisteanu Pircalabioru; Nicolae Corcionivoschi; Ozan Gundogdu; Mariana-Carmen Chifiriuc; Luminita Gabriela Marutescu; Bogdan Ispas; Octavian Savu
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

8.  It's That Time of Year Again.

Authors:  Stephen A Brunton
Journal:  Clin Diabetes       Date:  2020-01

Review 9.  A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.

Authors:  Susan Cornell
Journal:  J Clin Pharm Ther       Date:  2020-09       Impact factor: 2.512

10.  Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia.

Authors:  C A Gilroy; M E Capozzi; A K Varanko; J Tong; D A D'Alessio; J E Campbell; A Chilkoti
Journal:  Sci Adv       Date:  2020-08-26       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.